Q-omics provides the consensus-scored IFNWP2 profile across patient tissues and cancer cell-line models. IFNWP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IFNWP2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, IFNWP2 RNA expression shows 10,617 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, THCA, and THYM as cancer lineages where IFNWP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNWP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNWP2 survival associations across molecular data types. IFNWP2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNWP2 RNA expression–survival associations across cancer types. High IFNWP2 expression shows unfavorable associations in LUAD, ACC, LUSC, UCEC, SKCM and OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for IFNWP2 RNA expression.
This table summarizes IFNWP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IFNWP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNWP2 shows lower tumor expression in KIRC, KICH, BRCA and LUAD and higher tumor expression in THCA and HNSC. The THCA box plot shows higher IFNWP2 RNA expression in tumor versus normal tissue (log2 FC = +0.584, t-test p < 0.001).
This table shows molecular features associated with IFNWP2 in patient tissues and cancer cell lines. In patient samples, IFNWP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
